06/10/2017 Physiogenex presents the effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption at ADA 2017, San Diego, USA
Physiogenex has investigated the acute effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption in the Golden Syrian hamster model.
Dr. François Briand, Director of Research and Business Development at Physiogenex, will present the study results during the 77th American Diabetes Association 2017 scientific sessions in San Diego, CA, USA.
The oral presentation is scheduled during the oral abstract session (Lipid modifying interventions and their consequences AC-OR07, abstract#229) from 6:00pm-6:15am on Sunday, June the 11th, 2017.
If you wish to know more about running preclinical experiments with us, ask Physiogenex experts
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.
Please visit our website for more information